Preferred Label : tamoxifen;

Details


Main resources

You can consult :


https://www.cochrane.org/fr/CD014869/LIVER_quels-sont-les-benefices-et-les-risques-du-tamoxifene-dans-le-traitement-des-personnes-atteintes-dun
2024
United Kingdom
review of literature
french abstract
disease
tamoxifen
persons
carcinoma, hepatocellular
risk assessment
tamoxifen
hepatocellular carcinoma, nos
risks and benefits
disease of liver, nos

---
https://syngof.fr/documents-utiles/covid-19-recommandations-de-strategies-de-prevention-des-evenements-thromboemboliques-veineux-des-femmes-covid-et-utilisant-un-traitement-hormonal/
2020
France
coronavirus infections
pneumonia, viral
guideline
menopause
Hormonal contraception
female
tamoxifen
hormonotherapy
hospital admission, nos
hormones
hormone, nos
women
contraception, nos
menopause, nos
risk
contraception
tamoxifen
estrogen replacement therapy
hospitalization
menopause
female
hormones
risk
pandemics
COVID-19

---
https://www.sggg.ch/fileadmin/user_upload/Dokumente/3_Fachinformationen/1_Expertenbriefe/Fr/2_Tamoxifene_1996.pdf
1996
false
false
false
Switzerland
guideline
tamoxifen
expert testimony
expert opinion
Carcinoma
carcinoma
tamoxifen

---
Nous contacter.
02/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.